Onconova Therapeutics to Present at the Ladenburg Thalmann 2022 Healthcare Conference NEWTOWN, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...

Onconova Therapeutics Announces Updated Data from Investigator-sponsored Phase 1/2a Trial Evaluating Rigosertib in Combination with Nivolumab in Advanced KRAS-mutated Non-Small Cell Lung Cancer at the ESMO Congress 2022 Data show an early signal of efficacy in an extensively pre-treated population with 1 complete response and 2 partial responses achieved in 14 evaluable patientsResponses achieved in patients with 3...

BioNTech präsentiert auf ESMO-Kongress weitere ermutigende Daten aus Phase-1/2-Studie mit CAR-T-Programm BNT211 in schwer zu behandelnden soliden Tumoren Follow-up-Daten zeigen ermutigende Anzeichen für eine klinische Anti-Tumor-Aktivität sowie ein kontrollierbares Sicherheits- und Verträglichkeitsprofil; Daten bauen auf den positiven...

BioNTech Presents Encouraging Phase 1/2 Follow-up Data for CAR-T Candidate BNT211 in Hard-To-Treat Solid Tumors at ESMO Follow-up data further demonstrate encouraging signs of clinical anti-tumor activity and a manageable safety and tolerability profile, building on the positive interim data presented at AACR in...

ITM to Present Trial Design of Ongoing Phase III COMPOSE Study in Advanced Neuroendocrine Tumors at ESMO 2022 Garching / Munich, September 6, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that a scientific poster on the design of its second...